Skip to Main Content
Contribute Try STAT+ Today

Under pressure to appease investors, Sanofi (SNY) has twice in the past week agreed to pay hefty amounts of money to buy a pair of companies that specialize in treating blood disorders. In doing so, the drug maker is scrambling to remake itself as its key diabetes franchise struggles under pricing pressure.

The latest deal involves paying more than $4.8 billion for Ablynx (ABLYF), which is researching rare blood disorders and developing novel drugs based on so-called nanobodies that are found in the immune systems of llamas and alpacas. Just last week, the drug maker paid agreed to pay $11.6 billion for Bioverativ (BIVV) — and a pair of hemophilia treatments — that was spun off by Biogen (BIIB).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.